Pharmaceutical Companies in Nottingham: 66 Active Firms (2026)

Nottingham has 66 actively trading pharmaceutical companies in scope, a compact city-level cohort alongside the UK’s wider life-sciences market. Reported employment totals 105 people, which points to a list dominated by lean specialists rather than large manufacturing campuses. 4 companies report turnover above £5M, so revenue concentration sits in a small upper tier, while 12 were incorporated since 2022. That mix gives the city a practical base of established licence-holders and younger entrants, but not the depth seen in larger regional clusters.

Human medicines in the UK sit under the MHRA, with ABPI describing the agency’s remit across standards, clinical trial approvals, medicines licensing and pharmacovigilance. Manufacturing, assembly and import activity require an MHRA manufacturer’s licence, with good manufacturing practice compliance and site inspections built into the operating model. Wholesale supply to anyone other than the patient brings wholesale distribution licensing and good distribution practice obligations. Market access is also shaped by marketing authorisation and cost-effectiveness review, which means Nottingham firms selling into healthcare routes often face evidence, quality and documentation requirements before commercial scale becomes visible.

Further development appears likely to be incremental rather than spectacular. The cohort tends to favour regulated service models, clinical supply, quality assurance and distribution niches where permissioning and inspection readiness create barriers to casual entry. Scarcity of larger revenue operators suggests that some firms may remain specialist contractors rather than becoming broad manufacturers. At the same time, younger entrants give the market a renewal layer, particularly where documentation, storage, import or pharmacovigilance workflows can be delivered without major plant investment. Consolidation may come from buyers seeking licensed capacity, but the sector still looks more operationally constrained than venture-led.